HIRONIC

HIRONIC marked the 20th anniversary of its founding on July 12, 2026. The company was established in 2006 as SP Medical, a name derived from "Success Partner," and has since grown into a KOSDAQ-listed developer and manufacturer of medical aesthetic devices with a presence in more than 60 countries. Two Decades of Development HIRONIC's founding period (2006–2010) centered on the development of its first medical devices and the establishment of its early patent portfolio. Between 2011 and 2016, the company listed on KOSDAQ and introduced the DOUBLO line of devices, a technology platform later upheld through a defended patent ruling. From 2017 to 2020, HIRONIC received FDA and CE approvals for multiple device lines, expanding its distribution beyond the Korean market. The period from 2021 to 2023 saw continued growth in international distribution and industry recognition. Most recently, the company has launched SYNERJET PRO™ and MIGLOU™, both of which have received Korea MFDS approvals in 2026. Current Operations HIRONIC's product portfolio today includes SYNERJET PRO™, MIGLOU™, New Doublo™ (marketed in Korea as V-RO LIFTING™​), and PICOHI™, covering applications in skin treatment, body contouring, and related aesthetic procedures. The company continues to work with distributors and physicians across its international markets. In a statement marking the anniversary, HIRONIC said the milestone reflects two decades of work with its distributors, partner physicians, and patients, and that the company intends to continue developing new devices and expanding its international regulatory approvals in the years ahead.​ 

HIRONIC, a global medical aesthetic device company marking its 20th anniversary in 2026, announced today that its MIGLOU™ device has received medical device approval from Korea's Ministry of Food and Drug Safety (MFDS). The approval adds MIGLOU™ to HIRONIC's growing portfolio of MFDS-certified technologies, reinforcing the company's continued investment in clinically validated, next-generation aesthetic solutions for medical professionals worldwide.    A New Approach to Skin Tightening and ContouringMIGLOU™ is built on HIRONIC's proprietary 2.45GHz Focused Intensive Microwave (FIM) technology, engineered to deliver targeted energy for skin tightening and contouring treatments. The platform reflects HIRONIC's ongoing commitment to developing differentiated technologies that address evolving needs in the medical aesthetics field. The approval marks another step in HIRONIC's 20th anniversary year, reflecting the company's continued focus on research-driven development and a regulation-first approach to bringing new technologies to the global aesthetic market.Strengthening HIRONIC's Global Technology PortfolioThe MFDS approval positions MIGLOU™ alongside HIRONIC's established device lines — including New Doublo™, SYNERJET PRO™​, and PICOHI™  — as part of a comprehensive technology platform serving medical aesthetic partners in more than 60 countries. With MFDS, FDA, and CE certifications across its portfolio, HIRONIC continues to expand its footprint through a rigorous, regulation-first approach to product development.About HIRONICFounded in 2006, HIRONIC is a KOSDAQ-listed medical aesthetic device company celebrating its 20th anniversary in 2026. HIRONIC develops and manufactures energy-based aesthetic devices distributed across more than 60 countries, with a portfolio spanning HIFU, RF, laser, and needle-free delivery technologies.  

HIRONIC took part in IMCAS Asia 2026 (19th Edition), one of Asia's most prestigious aesthetic medicine conferences, held June 19–21 at The Athenee Hotel, Bangkok. In cooperation with Thai partner, HIRONIC presented its latest innovations in energy-based aesthetic devices to a global audience of practitioners and industry experts. A Showcase of HIRONIC's Core TechnologiesAt the booth, HIRONIC introduced three key devices spanning the company's core treatment categories: PICOHI™, HIRONIC's picosecond laser platform for pigmentation and skin revitalization; SYNERJET PRO™, the brand's needle-free triple-action delivery platform combining microjetting, electroporation, and cold plasma; and the flagship New Doublo™, HIRONIC's advanced MFU+RF platform for lifting and skin tightening. Together, the lineup gave attendees a comprehensive look at how HIRONIC's technologies address needs across skin pigmentation, scar remodeling, and skin tightening.  Expert Lecture Spotlights MIGLOU™'s Proprietary FIM TechnologyA highlight of the conference was the Expert Lecture delivered by Dr. Thitikom Limrattanamekha, held during the Laser & EBD Session at The Athenee Hotel. In his presentation, "MIGLOU™ 2.45 GHz: Precision UHF Technology for Non-Invasive Fat Lipolysis and Contouring," Dr. Thitikom outlined the clinical advantages of MIGLOU™'s focused intensive microwave (FIM) technology — a modality proprietary to HIRONIC and the first of its kind in the world. His lecture detailed how MIGLOU™'s precision UHF approach enables non-invasive fat lipolysis and body contouring with a distinct mechanism of action compared to existing energy-based technologies, drawing strong engagement from attending practitioners. Strengthening HIRONIC's Presence in Southeast AsiaIMCAS Asia 2026 offered HIRONIC an important opportunity to deepen its relationship with practitioners across Southeast Asia. As HIRONIC celebrates its 20th anniversary in 2026, events like IMCAS Asia continue to play a key role in the company's global expansion strategy, connecting its technologies with the clinicians and markets shaping the future of aesthetic medicine. HIRONIC thanks Dr. Thitikom Limrattanamekha for his insightful lecture, its Thai partner for their continued collaboration, and all attendees who visited our booth during the conference. For more information about PICOHI™, SYNERJET PRO™, New Doublo™, or MIGLOU™, please visit our website or contact your regional HIRONIC representative.  

Last Saturday, HIRONIC welcomed an elite audience of leading aesthetic experts and top users from Korea and Japan for a private launching preview — an intimate, high-level event dedicated to unveiling two groundbreaking new devices set to redefine the non-invasive aesthetics landscape. Two Landmark Innovations UnveiledThe event introduced two next-generation devices: an advanced contouring and face lifting platform powered by microwave technology, available for export as MIGLOU™, and a revolutionary needle-free injector that uniquely combines three technologies — micro-jetting, electroporation, and plasma — in a single platform, available for export as SYNERJET PRO™.Four Immersive Expert LecturesThe launch was enriched by four in-depth lectures delivered by four of Korea's foremost aesthetic experts, offering clinical insights, hands-on perspectives, and forward-looking analysis on both devices and the broader direction of non-invasive aesthetics.Expert Insights on HIRONICAcross the presentations, experts consistently highlighted what sets HIRONIC apart in a crowded market. HIRONIC devices are recognized for their exceptional build quality, and the brand has remained steadfastly focused on non-invasive technologies — always prioritizing reduced patient discomfort alongside improved clinical efficacy. It is this unwavering philosophy, experts noted, that allows HIRONIC devices to consistently outperform competitors.A New Standard in Microwave-Based ContouringOn the microwave contouring device, experts drew particular attention to its proprietary FIM (Focused Intensive Microwave) technology — a uniquely advanced feature that enhances treatment efficiency while delivering the same energy output. This innovation, experts emphasized, is an entirely distinctive advancement that elevates MIGLOU™ (export name) to true second-generation microwave technology status, setting it apart from all currently available solutions and creating clear, immediate market value.Redefining Needle-Free DeliveryRegarding the triple-technology needle-free injector, experts were equally emphatic: combining micro-jetting, electroporation, and plasma into a single device is not incremental progress — it is a meaningful leap forward. When these three technologies work in synergy, they significantly enhance active ingredient absorption, a benefit now supported by recent clinical studies. Experts underscored that SYNERJET PRO™ (export name) directly overcomes the limitations of currently available needle-free solutions, positioning it as an undeniable step toward shifting the aesthetics industry from the injection era into a new age of advanced needle-free delivery.Setting the Course for the Future of Non-Invasive AestheticsThe private launch preview was more than a product reveal — it was a statement of direction. With two devices that each advance their respective categories in meaningful, clinically relevant ways, HIRONIC once again demonstrated its commitment to pushing the boundaries of non-invasive aesthetics. As both platforms make their way to markets worldwide, the industry will be watching closely — and if the response from Korea and Japan's top experts is any indication, the impact is set to be significant.​

HIRONIC announced on May 15 that it has signed an exclusive supply agreement with EMAGE Medical, a U.S.-based medical device distribution company, for its “next-generation RF combination platform” in the United States.The agreement will be carried out under an OEM model and will remain valid for two years from May 2026. The contract is also structured to allow an extension through mutual agreement between the two companies.EMAGE Medical is a medical device distribution company headquartered in Charlotte, North Carolina, and has established specialized medical aesthetic sales channels in the United States. During the contract period, EMAGE Medical plans to supply HIRONIC’s platform device under a locally customized brand, based on its exclusive sales and distribution rights across the U.S. market.The agreement includes a minimum annual purchase quantity clause. According to the company, this provision is intended to ensure active sales activities by the partner company. At the same time, the agreement includes conditions allowing the minimum purchase obligation to be adjusted in consideration of regulatory changes, including the FDA approval timeline, thereby balancing risk management for both parties.Based on technical and regulatory cooperation with EMAGE Medical, HIRONIC will support the local brand launch in the United States. The company also plans to build clinical case data and establish a network of key opinion leaders, or KOLs.The “next-generation RF combination platform” is characterized by the integration of RF, or radiofrequency, and Cold Plasma technologies into a single device. With five types of handpieces, including RF microneedling, Cold Plasma, and Circle monopolar RF, the platform supports a wide range of clinical applications, including skin lifting, tightening, scar and wrinkle improvement, and women’s health.In particular, the company explained that the sequential combination protocol using RF microneedling and Cold Plasma is designed to enhance collagen activation while minimizing post-procedure inflammation.A HIRONIC official stated, “This exclusive supply agreement in the United States, the world’s largest medical aesthetic market, demonstrates that our technology has been recognized in the global market.” The official added, “We will continue to strengthen our competitiveness in the medical aesthetic market by enhancing our technological capabilities and expanding strategic partnerships.” Reporter: Seong-hye Kim, hankyung.com[shkimmy@hankyung.com]Translation of the original articleOriginal article link: https://www.hankyung.com/article/202605158616O​

HIRONIC won the grand prize in the medical aesthetic device category for the ninth consecutive year at Money Today’s “2026 Service Customer Satisfaction Awards Chosen by Consumers,” held on April 29 at the Press Center in Jung-gu, Seoul.The Service Customer Satisfaction Awards Chosen by Consumers are presented to outstanding companies that achieve customer satisfaction by providing high-quality services across various industries.HIRONIC is a company specializing in medical aesthetic devices that implement technologies such as HIFU, or high-intensity focused ultrasound, RF, or radiofrequency laser, and Micro-Jetting. Its flagship product is V-RO ADVANCE, exported as New Doublo 2.0™, which was the world’s first device to enable three procedures—HIFU, RF, and Micro Needle—in a single platform.HIRONIC is introducing its needle-free energy devices, SYNERJET and SYNERJET PRO™, to both the domestic and global markets. SYNERJET gently refines the skin surface through uniform jetting technology, precise pressure control, and plasma technology. It also reduces user fatigue during extended use through its lightweight handpiece and intuitive operating system.SYNERJET PRO™ is a medical device that combines Micro-jetting, Electroporation, and Plasma technologies. It is designed to enable more precise and uniform procedures. Reporter: Nami HeoTranslation of the original articleOriginal article link: https://www.mt.co.kr/industry/2026/04/29/2026042814203330182

HIRONIC announced that its non-invasive skin improvement medical device, SYNERJET PRO®, has officially obtained domestic medical device approval after successfully passing the Medical Device Technical Document Review (SR) by the Ministry of Food and Drug Safety (MFDS) and completing the certification application process through the National Institute of Medical Device Safety Information.This approval officially recognizes that HIRONIC’s independently developed needle-free microjet technology complies with domestic medical device standards and specifications. It is expected to serve as an opportunity to strengthen both HIRONIC’s competitiveness in the domestic market and its credibility in the global market.SYNERJET PRO® is a non-invasive drug and cosmetic solution delivery medical device based on Needle-free Microjetting technology independently developed by HIRONIC. It delivers active ingredients evenly into the skin layers using pressure alone, without needles, making it applicable to a wide range of dermatology and plastic surgery procedures, including treatments for patients with needle phobia. By expanding its lineup from the existing SYNERJET to the upgraded SYNERJET PRO®, HIRONIC is demonstrating strong potential in multiple application areas, including skin elasticity improvement, hydration, and drug delivery.During this review, HIRONIC received final conformity judgment from the Korea Testing & Research Institute (KTR) for SYNERJET PRO® as a combination medical device consisting of a jet injector and a low-frequency stimulator.Obtaining domestic approval for SYNERJET PRO® carries significant business value for HIRONIC. As SYNERJET, which had previously been supplied only for export, can now be officially used by domestic dermatology clinics, plastic surgery clinics, and medical aesthetic institutions, HIRONIC has secured a foundation for domestic sales growth. In addition, based on MFDS approval, which is highly trusted internationally, the company is expected to further strengthen its negotiating power with overseas buyers and partners.Furthermore, by securing domestic medical device status, HIRONIC will be able to formalize clinical cooperation with Korean medical specialists and build an official KOL (Key Opinion Leader) network. This approval is also expected to serve as an important precedent for future approval applications for next-generation needle-free injector lineups, including SYNERJET PRO®.HIRONIC plans to immediately proceed with the certification application to the National Institute of Medical Device Safety Information (NIDS), with the goal of receiving the final approval certificate within April 2026. After receiving the certificate, the company plans to accelerate individual certifications for major global markets, including the United States, and further establish its positioning as a premium needle-free injector brand. Reporter: Wonji Leenews21g@etnews.comOriginal Article: https://www.etnews.com/20260422000210​ 

HIRONIC participated in the American Society for Laser Medicine and Surgery (ASLMS), one of the world’s leading laser medicine conferences, where it showcased its key devices as part of its efforts to expand into the North American market.Celebrating its 45th edition this year, ASLMS is a representative conference in the field of laser-based medical devices. The event was held from May 7 to 9 at the Savannah Convention Center in Georgia, USA. With the participation of numerous global medical professionals and industry stakeholders, ASLMS served as a major platform for sharing the latest technological trends and clinical application cases.At the conference, HIRONIC introduced its core technologies and product competitiveness, focusing on expanding its presence in the global market. In particular, the company showcased the application methods and differentiated technological structures of its major export models, including MIGLOU™, which applies FIM™​ (Focused Intensive Microwave) technology; SYNERJET PRO™, a non-invasive medical device designed to deliver active ingredients using Needle-free Microjetting technology; and NEW DOUBLO 2.0™, a comprehensive lifting platform that combines HIFU and RF technologies.In addition, HIRONIC conducted device demonstrations and consultations at its on-site booth, expanding contact points with medical professionals and buyers from various countries. Through these activities, the company strengthened its brand awareness in the North American market and explored practical opportunities for future business cooperation.A HIRONIC official stated, “ASLMS is a key conference where global medical professionals and industry stakeholders gather in one place, making it an important opportunity for us to directly present our technological capabilities and product competitiveness.” The official added, “Through our participation in this event, we have further accelerated our entry into the North American market in line with the global growth of K-beauty, and we will continue to expand our presence in overseas markets.”​ 

Hironic Co., Ltd. (CEO Lee Jin-woo) announced that it hosted a 'VVIP Partners Meeting' on the 20th at Park Hyatt Seoul, inviting global partner companies and Key Opinion Leaders (KOLs).This event was organized as a platform for communication where partners and medical professionals from various countries gathered to share clinical applications of Hironic's major medical devices, thereby enhancing technological competitiveness and brand reliability. In-depth discussions on product-specific features and actual clinical cases took place on-site.In particular, Hironic presented product details and clinical cases focusing on its core export devices: 'New Doublo 2.0', 'SYNERJET PRO™', and 'MIGLOU™'.It was emphasized that 'New Doublo 2.0', known domestically as 'V-RO LIFTING', combines Micro-Focused Ultrasound (MFU) and Radio Frequency (RF) to enable various customized treatments tailored to individual skin conditions.'SYNERJET PRO™', the export model of the KC-certified domestic 'SYNERJET', is an advanced medical aesthetic device that combines micro-jetting, electroporation, and plasma technologies to uniformly deliver active ingredients deep into the dermal layer.'MIGLOU™' garnered particularly intense interest during this meeting. Introduced domestically as 'MIGLOW', this device is designed to effectively deliver energy to targeted areas while minimizing the burden on the skin's surface by applying 2.45 GHz-based Ultra High Frequency (UHF) energy technology and a cooling system. The presentation also highlighted its versatility across various areas, including the face and body, and its ability to provide customized care through multiple handpieces.Active Q&A sessions regarding the technical characteristics, implementation feasibility, and application scope of 'MIGLOU™' took place on-site. Expectations were high for it as a next-generation aesthetic medical device due to its superior energy utilization efficiency compared to conventional RF equipment.A representative from Hironic stated, "Through this meeting, we have reinforced our collaborative relationships with global partners, and we will continue to strive for sustained improvement in product competitiveness and the expansion of our global network."​  

 Hironic Co., Ltd. announced that it has successfully concluded its participation in ‘KIMES 2026’ (Korea International Medical & Hospital Equipment Show), the largest medical device exhibition in Korea.KIMES is Korea’s premier exhibition that offers a comprehensive look at the latest technologies and trends in the medical industry. This year’s event once again garnered significant attention from industry professionals by showcasing a diverse array of medical devices and healthcare solutions.At the exhibition, Hironic showcased its flagship aesthetic medical devices, including ‘MIGLOU,’ ‘V-RO LIFTING,’ and ‘SYNERJET,’ actively engaging in product demonstrations and consultations with domestic and international medical professionals and buyers. Visitors to the booth observed live device demonstrations, leading to specific inquiries regarding the features and practical applications of the products.The new product, ‘MIGLOU,’ drew particular attention. Designed with 2.45 GHz-based UHF (Ultra-High Frequency) energy technology and an integrated cooling system, it is engineered to effectively deliver energy to targeted areas while minimizing strain on the skin's surface. It captured visitors' interest with its versatility, offering a variety of handpieces that allow for comprehensive treatments across both the face and the entire body.Additionally, ‘SYNERJET,’ a skin booster delivery device utilizing a microjet system, was highlighted for its ability to evenly distribute active ingredients while minimizing physical irritation.‘V-RO LIFTING,’ a device combining High-Intensity Focused Ultrasound (HIFU) and Radio Frequency (RF), was also featured. By simultaneously utilizing two types of energy from a single device, it enables a wide range of customized treatments tailored to individual skin conditions.An official from Hironic stated, "At KIMES 2026, we successfully showcased the technological prowess and practical applications of our core products to medical professionals and buyers from home and abroad." They added, "Having witnessed the enthusiastic response from our booth visitors, we will continuously strive to expand our presence in the global market and strengthen the competitiveness of our products."

Hironic Co., Ltd., a company specializing in aesthetic medical devices, announced on the 18th that it will showcase its new product, “MIGLOU,” at “KIMES 2026” (Korea International Medical & Hospital Equipment Show), the largest medical device exhibition in Korea. KIMES is Korea’s premier medical device exhibition, offering a comprehensive look at the latest trends and technologies in the medical industry. It is a major global medical industry event that attracts a massive number of domestic and international medical device companies, medical professionals, and buyers each year. At KIMES 2026, a variety of cutting-edge medical devices and smart healthcare technologies are scheduled to be introduced. During this exhibition, Hironic plans to capture the attention of domestic and international medical professionals and buyers by showcasing its new product 'MIGLOU' alongside its core lineup of aesthetic medical devices. MIGLOU is a device designed based on 2.45GHz Ultra-High Frequency (UHF) technology. By applying CNF (Complex Near Focusing) matching technology, it enables highly precise energy delivery to the target area. Additionally, it features a safety-focused design that utilizes a contact cooling system and built-in handpiece sensors during treatments. Its utility is further enhanced by supporting a variety of handpieces designed for both face and body care. Throughout the KIMES 2026 exhibition, Hironic plans to directly demonstrate MIGLOU's technological capabilities to medical professionals and buyers through on-site demonstrations and product consultations. Furthermore, as part of its strategy to expand into the global market, Hironic will actively seek collaborative opportunities with international medical professionals and partners, and conduct business meetings with overseas buyers. An official from Hironic stated, "MIGLOU, which we are unveiling at KIMES 2026, is a device developed to reflect the diverse needs of the aesthetic dermatology market." The official added, "Through continuous research and development, we plan to keep introducing innovative solutions that enhance satisfaction for both medical professionals and patients." Meanwhile, Hironic has been bolstering its competitiveness in the aesthetic medical device market through ongoing investments in Research and Development (R&D) and the expansion of its global distribution network. The company recently solidified its foundation for growth by securing a strategic investment from Cactus Private Equity (Cactus PE). Building on this momentum, Hironic is expected to continuously drive the development of next-generation technologies in the medical aesthetic field and further expand its presence in the global market.

 HIRONIC, a company specializing in aesthetic medical devices, announced that it participated in the 'IMCAS World Congress 2026', the world's largest aesthetic medicine congress held in Paris, France, where it shared its portfolio of energy-based aesthetic devices and technological direction with global medical professionals.The IMCAS World Congress is an international conference attended by dermatologists, plastic surgeons, and medical device industry professionals from around the world. It serves as a prominent platform for active discussions and exchanges on the latest technological trends and industry developments.Operating a dedicated booth at IMCAS 2026, Hironic showcased a range of aesthetic equipment featuring various energy-based technologies, including HIFU, RF, and UHF. A key highlight was the company's approach of presenting combinable device configurations tailored to specific clinical environments and purposes, rather than limiting its focus to a single technology or device.During the event, Hironic also hosted a separate 'IMCAS VVIP Partners Meeting' to foster networking with global partners and medical professionals. At this meeting, participants exchanged views on Hironic's brand direction and potential future collaborations.Additionally, an official IMCAS program session featured a presentation on the practical field applications and clinical experiences of Hironic's SYNERJET PRO™ (export model), providing an opportunity to deepen the audience's understanding of the brand and its technology.At the booth, Hironic provided detailed demonstrations of its stable energy control technology, user-centric design approach, and user interfaces that reflect actual clinical environments. According to the company, these features garnered significant interest from a large number of international medical professionals.An official from Hironic stated, "IMCAS is a valuable platform to communicate directly with global medical professionals and to identify technological trends and market demands. Through our participation this year, we were able to share Hironic's brand identity and our vision for energy-based aesthetic device technology on the international stage." Moving forward, Hironic plans to further elevate its technological excellence and continuously strengthen its competitive edge in the aesthetic medical device sector through ongoing participation in global congresses and various networking opportunities.

HIRONIC Co., Ltd. (CEO: Jin-Woo Lee), a global manufacturer of aesthetic medical devices, announced that Dr. Kibum Kim, Executive Director of the Society, delivered a lecture on HIRONIC’s V-RO Lifting at the 51st Fall Scientific Meeting of the Korean Society for Laser, Dermatology and Trichology (KSLDT), held on December 14 at the Grand InterContinental Parnas Seoul. The conference attracted approximately 4,500 medical professionals, making it one of the largest academic gatherings in Korea dedicated to laser- and energy-based dermatologic treatments. The Korean Society for Laser, Dermatology and Trichology hosts regular academic conferences each year to facilitate scientific exchange among dermatologists and related medical specialists. During the lecture, Dr. Kim introduced current trends in aesthetic lifting procedures, with a particular focus on the multi-layer targeting approach, which considers the skin’s structural layers in a comprehensive and stratified manner. Also presented during the session, V-RO Lifting is HIRONIC’s next-generation lifting device, designed to deliver high-intensity focused ultrasound (HIFU) and radiofrequency (RF) simultaneously within a single system. This integrated design supports a lifting approach that addresses both deep and superficial skin layers, aligning with the growing trend toward multi-layer targeted lifting techniques in aesthetic medicine. A HIRONIC representative stated, “Through this lecture at the Korean Society for Laser, Dermatology and Trichology, we were able to academically share both current lifting treatment trends and the technological direction of combining HIFU and RF. HIRONIC will continue to actively engage in academic conferences and scientific activities to communicate closely with medical professionals and contribute to the advancement of aesthetic technologies.”​ 

HIRONIC Co., Ltd. (CEO: Jinwoo Lee), a global manufacturer and supplier of aesthetic medical devices, announced that its HIFU-based lifting system, NEW DOUBLO 2.0 (known domestically as V-RO Advance), has obtained official import approvals from key regulatory authorities in the Middle East, including the Ministry of Health and Prevention (MOHAP) of the United Arab Emirates, the Ministry of Public Health (MOPH) of Qatar, and the Saudi Food and Drug Authority (SFDA). NEW DOUBLO 2.0 is the latest model in HIRONIC’s flagship DOUBLO HIFU series, incorporating advanced focusing technology and precise energy control algorithms to deliver stable and consistent treatment outcomes. The platform supports a versatile configuration of treatment handpieces, including HIFU, RF microneedling (RM), and RF, enabling physicians to address a wide range of clinical needs such as skin lifting, elasticity improvement, pore refinement, and skin tone enhancement. As a result, demand for the system continues to grow rapidly across global markets. In recent months, HIRONIC has conducted on-site clinical training and operational education programs for NEW DOUBLO 2.0 in both the UAE and Saudi Arabia. These programs provided local medical professionals with comprehensive instruction, ranging from in-depth explanations of core technologies to hands-on training sessions, and received strong interest and positive feedback from clinics and practitioners in the region. Following the latest import approvals, HIRONIC plans to further expand collaboration with regional partners while strengthening communication and engagement with the Middle Eastern market. “Demand for premium aesthetic treatments is growing rapidly across the Middle East,” said a representative from HIRONIC. “With consecutive import approvals in the UAE, Saudi Arabia, and Qatar, we aim to actively highlight the technological competitiveness of NEW DOUBLO 2.0 and further solidify our brand presence in the region.” Meanwhile, HIRONIC continues to expand global regulatory approvals for NEW DOUBLO 2.0, including ongoing processes in the United States (FDA) and Indonesia (KEMENKES RI), as part of its broader strategy to strengthen its global footprint. 

SEOUL, Korea – Global aesthetic medical device company HIRONIC Co., Ltd. announced that a lecture featuring its latest device, SYNERJET, was held on November 16 at the 7th Annual Scientific Meeting & International Symposium of the Korean Lifting Society, hosted at COEX Convention Center in Seoul. The event convened leading domestic and international experts in lifting and skin treatment to share emerging trends and technologies. As the demand rises for non-invasive skin booster solutions that minimize damage while enhancing active ingredient delivery, HIRONIC’s SYNERJET garnered significant attention as a cutting-edge response to this trend.Dr. Sang-Hoon Lee, Medical Director of YEPPEUMJUYI Clinic, led the lecture, focusing on the key factors that determine treatment outcomes—absorption depth, skin hydration, and spray control. Highlighting the differences between conventional needle-based methods and SYNERJET’s needle-free technology, Dr. Lee presented clinical data underscoring the device’s uniform spray mechanism and efficient ingredient delivery. His insights drew strong interest from attending practitioners. SYNERJET is HIRONIC’s latest needle-free device that uses microjet technology to deliver skin boosters with minimal surface damage. The system ensures precise control and high stability, making it a versatile solution suitable for various skin conditions. Compared to existing needle-free devices, SYNERJET is highly rated for its technical precision and user safety. A HIRONIC spokesperson stated, “SYNERJET is designed to offer a delicate yet precise solution, combining safety and convenience. We will continue to strengthen our market competitiveness by collaborating with medical experts and enhancing trust in our technologies.”​